Escalon Medical Corp (ESMC) — SEC Filings
Escalon Medical Corp (ESMC) — 9 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 6 10-Q, 2 10-K, 1 8-K.
View Escalon Medical Corp on SEC EDGAR
Overview
Escalon Medical Corp (ESMC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: ESCALON MEDICAL CORP (ESMC) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $239,852, a substantial rise from the $32,217 net loss in the same period of 2024. This deterioration was primarily driven by a loss from operations of $202,751 in Q3 2025,
Sentiment Summary
Across 9 filings, the sentiment breakdown is: 2 bearish, 7 neutral. The dominant filing sentiment for Escalon Medical Corp is neutral.
Filing Type Overview
Escalon Medical Corp (ESMC) has filed 6 10-Q, 2 10-K, 1 8-K with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (9)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 14, 2025 | 10-Q | ESMC's Net Loss Widens Sharply Amid Revenue Dip, Going Concern Doubts | high |
| Sep 29, 2025 | 10-K | Escalon Medical Faces 'Going Concern' Doubt Despite Recent Profitability | high |
| May 14, 2025 | 10-Q | Escalon Medical Corp. Files 10-Q for Q3 2025 | medium |
| Apr 4, 2025 | 8-K | Escalon Medical Corp. Changes Certifying Accountant | low |
| Feb 14, 2025 | 10-Q | Escalon Medical Corp. Reports Q2 Financials | low |
| Nov 14, 2024 | 10-Q | Escalon Medical Corp. Q3 2024 Revenue Reported | low |
| Sep 30, 2024 | 10-K | Escalon Medical Corp. Files 2024 10-K | low |
| May 14, 2024 | 10-Q | Escalon Medical Corp. Files 10-Q for Period Ending March 31, 2024 | |
| Feb 14, 2024 | 10-Q | Escalon Medical Corp. Files 10-Q for Period Ending December 31, 2023 | low |
Risk Profile
Risk Assessment: Of ESMC's 8 recent filings, 2 were flagged as high-risk, 1 as medium-risk, and 5 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2,675,321 |
| Net Income | -$239,852 |
| EPS | -$0.03 |
| Total Assets | $4,581,639 |
Key Executives
- Chief Executive Officer
- Chief Operating Officer
Industry Context
Escalon Medical Corp operates in the medical device sector, which is characterized by innovation, regulatory hurdles, and competitive pressures. Companies in this space often require significant R&D investment to develop new products and maintain market share. The current economic climate may also impact healthcare spending and device adoption rates.
Top Tags
10-Q (4) · financials (4) · Medical Devices (2) · Ophthalmology (2) · Going Concern (2) · assets (2) · liabilities (2) · Financials (2) · Assets (2) · Debt (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $239,852 | Increased significantly from $32,217 in Q3 2024 |
| Total revenues for Q3 2025 | $2,675,321 | Decreased by 3.8% from $2,781,346 in Q3 2024 |
| Loss from operations for Q3 2025 | $202,751 | Increased from $26,955 in Q3 2024 |
| Research and development expenses for Q3 2025 | $216,098 | Increased by 53.4% from $140,859 in Q3 2024 |
| Total assets as of September 30, 2025 | $4,581,639 | Decreased from $4,993,059 as of June 30, 2025 |
| Net cash provided by operating activities for Q3 2025 | $85,008 | Positive, but company still has going concern issues |
| Shares of common stock outstanding | 7,415,329 | As of November 13, 2025 |
| Basic loss per share for Q3 2025 | $0.03 | Increased from $0.01 in Q3 2024 |
| accumulated deficit | $68.4 million | as of June 30, 2025, indicating significant historical losses |
| market value of non-affiliate common equity | $386,652 | as of December 31, 2024, reflecting a small market capitalization |
| shares of common stock outstanding | 7,415,329 | as of September 26, 2025 |
| R&D expenditures | $753,000 | for fiscal year ended June 30, 2025, an increase from $688,000 in 2024 |
| total employees | 39 | as of June 30, 2025, indicating a small operational scale |
| U.S. patents | 2 | covering company technology, but deemed to have minimal impact on revenue |
| Total Assets | $35.0B | As of March 31, 2025, indicating the company's total resources. |
Frequently Asked Questions
What are the latest SEC filings for Escalon Medical Corp (ESMC)?
Escalon Medical Corp has 9 recent SEC filings from Feb 2024 to Nov 2025, including 6 10-Q, 2 10-K, 1 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ESMC filings?
Across 9 filings, the sentiment breakdown is: 2 bearish, 7 neutral. The dominant sentiment is neutral.
Where can I find Escalon Medical Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Escalon Medical Corp (ESMC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Escalon Medical Corp?
Key financial highlights from Escalon Medical Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ESMC?
The investment thesis for ESMC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Escalon Medical Corp?
Key executives identified across Escalon Medical Corp's filings include Chief Executive Officer, Chief Operating Officer.
What are the main risk factors for Escalon Medical Corp stock?
Of ESMC's 8 assessed filings, 2 were flagged high-risk, 1 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Escalon Medical Corp?
Forward guidance and predictions for Escalon Medical Corp are extracted from SEC filings as they are enriched.